Limit search to available items
58 results found. Sorted by relevance | date | title .
Book Cover
E-book
Author Ahmad Salehi

Title The Human Hypothalamus: Neuropsychiatric Disorders
Published Elsevier 2021

Copies

Description 1 online resource
Contents Intro -- The Human Hypothalamus: Neuropsychiatric Disorders -- Copyright -- Foreword -- Preface -- The HCN volumes on the Human Hypothalamus -- The hypothalamus: Arbitrary borders -- References -- Contributors -- Contents -- Contents of related volumes -- Chapter 1: Introduction: The human hypothalamus and neuropsychiatric disorders -- Section 21Continued from the previous volume.: Trauma and Iatrogenic Disorders -- Section 22: Neurobehavioral Disorders -- Section 23: Epilepsy -- Section 24: Neurodegenerative Disorders -- Section 25: Olfactory System -- Section 26: Autonomic and Sleep Disorders -- Section 27: Addiction and Pain -- Section 28: Critical Care and Brain Death -- References -- Section 21: Trauma and iatrogenic disorders -- Chapter 2: Chronic traumatic encephalopathy and the nucleus basalis of Meynert -- Introduction -- Pathologic Features of CTE -- CTE Tau Pathological Staging -- Nucleus Basalis of Meynert in CTE -- Cholinergic Basal Forebrain Subfields -- Septal (Ch1) and diagonal band (Ch2-Ch3) cholinergic neurons -- Nucleus basalis (Ch4) cholinergic neurons -- Cholinergic nbM Dysfunction in CTE -- Tau NFT Pathology Within the nbM in CTE -- p62 profiles within the nbM in CTE -- Transactive response DNA-binding protein of 43 (TDP-43 or TARDBP) in the nbM in CTE -- Amyloid Pathology in the nbM in CTE -- nbM Cortical Cholinergic Disconnection in CTE -- White Matter Disruption of nbM Axons in CTE -- Transcript Expression in CTE -- Cholinergic Transcript Dysregulation in Tau-Containing nbM Neurons in CTE -- Chrnb2 dysregulation in nbM neurons in CTE -- Dopaminergic transcript dysregulation in tau positive nbM neurons in CTE -- Calcium transcript dysregulation in tau positive nbM neurons in CTE -- Endocytic transcript dysregulation in tau positive nbM neurons in CTE
Cyclic adenosine monophosphate transcript dysregulation in tau positive nbM neurons in CTE -- Lissencephalic-1 transcript dysregulation in tau positive nbM neurons in CTE -- Chloride channel transcript dysregulation in tau positive nbM neurons in CTE -- Clinical Consequences of nbM Pathobiology in CTE -- Conclusions -- Acknowledgments -- References -- Section 22: Neurobehavioral disorders -- Chapter 3: Hypothalamic stress systems in mood disorders -- Stress System Dysfunction in Mood Disorders -- CRH and AVP -- Oxytocin -- Neuropeptides S and Y -- Orexins -- Translation of Neuropeptide Pharmacology Into Novel Medicines -- Corticotropin-releasing hormone (CRH)-Receptor type 1 (CRHR1) antagonists for treatment of major depr -- Vasopressin (AVP) 1B (V1b)-receptor antagonists for treatment of acute major depression -- Dual orexin receptor antagonists (DORAs) for treatment of insomnia and depression -- Conclusion -- References -- Chapter 4: Light therapy for mood disorders -- Introduction -- The beginning: Seasonal affective disorder -- Etiology of seasonal affective disorder -- Pathophysiology of (Peripartum) Mood Disorders -- The role of the hypothalamus-pituitary-adrenal axis -- The peripartum hypothalamus-pituitary-adrenal axis -- Fetal programming of the hypothalamus-pituitary-adrenal axis -- The role of the circadian rhythm -- The peripartum circadian rhythm -- Working Mechanisms of Light Therapy -- Clinical Studies of Light Therapy -- Light therapy for depression -- Light therapy for depression during pregnancy -- Light therapy for postpartum depression -- Light therapy for bipolar disorder -- Conclusions -- References -- Chapter 5: Neurobiology of peripartum mental illness -- Introduction to the Parental Brain -- Peripartum Mental Illness Occurs in One in Seven Women -- Neurobiology of Peripartum Mental Illness -- Peripartum anxiety disorders
Peripartum depression -- Substance use disorder in the peripartum period -- Other peripartum mental illnesses -- Other Factors Influencing Peripartum Mental Illness -- Concluding Remarks and Future Directions -- Acknowledgments -- References -- Chapter 6: The hypothalamo-pituitary-adrenal axis and the autonomic nervous system in burnout -- Introduction -- The burnout concept -- Clinical burnout -- Hypothalamo-Pituitary-Adrenal Axis in Burnout -- Basal HPA axis activity -- Cortisol awakening response -- Diurnal HPA axis activity -- Hair cortisol -- Response to challenges -- Longitudinal studies -- Anabolic hormones -- Autonomic System in Burnout -- Resting autonomic activity -- Response to challenges -- Longitudinal studies -- Methodologic Aspects -- Summary -- References -- Chapter 7: Posterior hypothalamus as a target in the treatment of aggression: From lesioning to deep brain stimulation -- Introduction -- Clinical Correlates of Aggression -- Laboratory Experiences: Roots of Surgical Approach for Aggressive Disorders -- At the Dawn of Surgery for Aggressive Disorders: The Lesional Era -- A Step Into Brain Stimulation: The DBS Era -- From the Target to the Circuit -- Debate around the target: ̀̀Posterior hypothalamuś́ or ̀̀A region posterior to the hypothala -- Circuit modulation -- Conclusions -- References -- Chapter 8: The implications of hypothalamic abnormalities for schizophrenia -- Introduction11Abbreviations used in the chapter are listed at the end of the chapter before References section. -- Hypothalamic Gross Anatomic Pathology in Schizophrenia -- Hypothalamic Cell Pathology in Schizophrenia -- Concentrations of Classical Neurotransmitters and Their Metabolites -- Changes in Hypothalamic Neurosecretory Neurons -- Alterations of Hypothalamic-Releasing and Inhibiting Factors Which Regulate Hormonal Axes
Alteration of Peptide Hormones Regulating Food Intake, Appetite, and Satiety -- Alteration of Hypothalamic Opioid Peptides: POMC, Endorphins, and Enkephalins -- Alterations in the Expression of Susceptibility Genes for Schizophrenia -- Role of the Hypothalamus in Sleep Disturbances in Schizophrenia -- Disease-Related Neuroinflammatory and Neuroimmune Disturbances and the Impact of the Hypothalamus -- Conclusions -- References -- Chapter 9: The promiscuity of the oxytocin-vasopressin systems and their involvement in autism spectrum disorder -- Introduction: Oxytocin and Vasopressin Synthesis, Gene Structure, and Function -- Evolutionary History of Oxytocin and Vasopressin Ligands and Receptors -- Oxytocin and Vasopressin Ligand and Receptor Distribution in the Human and Mouse Brain -- Oxytocin and Vasopressin Regulate Social Behaviors -- Gene blockade and activation studies (knockout, pharmacological, chemogenetic, optogenetic) -- Oxytocin/vasopressin concentration and administration studies -- Epigenetic studies -- Single-nucleotide polymorphism (SNP) studies -- Oxytocinergic and Vasopressinergic Systems Are Impaired in ASD and Related Animal Models -- Nonhuman animal models -- Human patients -- Treatments for ASD Targeting the Oxytocinergic and Vasopressinergic Systems -- Treatments targeting the oxytocin system in adults -- In nonhuman animal models -- In human patients -- Treatments targeting the oxytocin system during development -- In nonhuman animal models -- In human patients -- Treatments targeting the vasopressin system -- In nonhuman animal models -- In human subjects -- Oxytocin and behavioral therapies -- Conclusion -- References -- Section 23: Epilepsy -- Chapter 10: Gelastic seizures and the hypothalamic hamartoma syndrome: Epileptogenesis beyond the lesion? -- Introduction
MRI-Based Classification of HH With Regard to Clinical Phenotypes -- Seizure Semiology in Epilepsy With HH -- Gelastic seizures -- Dacrystic seizures -- Other seizure types -- Epilepsy with HH as a Model of Secondary Epileptogenesis -- Secondary epileptogenesis: Basis and principles -- Secondary epileptogenesis and hypothalamic kindling: Experimental data -- Intrinsic epileptogenicity of the HH: Arguments from invasive recordings -- Human data arguing for secondary epileptogenesis in HH -- Secondary Epileptogenesis and the Concept of Epileptogenic Networks -- Illustrative cases from Marseille series -- Conclusions -- References -- Chapter 11: The interactions between reproductive hormones and epilepsy -- Introduction -- The Effects of Hormones on Epilepsy -- Neuroactive properties of reproductive steroid hormones -- Estradiol -- Progesterone and its metabolites -- Androgens -- Effects of hormones on epilepsy-Clinical implications -- Puberty -- Catamenial epilepsy -- Changes in seizure frequency during pregnancy and effect of prior history of catamenial epilepsy -- Menopause -- Hormonal treatment -- The Effects of Epilepsy on Reproductive Endocrine Function -- The role of epilepsy in women -- The role of epilepsy in men -- Antiepileptic Drug-Related Mechanisms -- Reproductive endocrine effects of antiepileptic drugs in men -- Phenobarbital, phenytoin, and carbamazepine -- Valproate -- Oxcarbazepine -- Lamotrigine -- Other new antiepileptic drugs -- Reproductive endocrine effects of AEDs in male subjects with epilepsy during pubertal development -- Reproductive endocrine effects of antiepileptic drugs in women -- Phenobarbital, phenytoin, and carbamazepine -- Valproate -- Oxcarbazepine -- Lamotrigine -- Other new antiepileptic drugs -- Reversibility of the reproductive endocrine effects of antiepileptic drugs after discontinuation of the medication
Subject Hypothalamus.
Hypothalamus
Hypothalamus
Form Electronic book
Author Paul J. Lucassen
Felix Kreier
Ruud M. Buijs
Dick F. Swaab
ISBN 9780128199732
0128199733
9780128199749
0128199741